Synthesis and activity of novel and selective Iks-channel blockers

Journal of Medicinal Chemistry

Volumn 44, Issue 23, 2001, Pages 3831-3837

  Gerlach, U ^a   Brendel, J ^a   Lang, H J ^a   Paulus, E F ^a   Weidmann, K ^a   Bruggemann A ^b   Busch, A E ^b   Suessbrich, H ^b   Bleich, M ^c   Greger, R ^c  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b DG Cardiovascular Diseases   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CHROMANOL; N (3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL) N METHYL ETHANESULFONAMIDE; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; NONHUMAN; OOCYTE; POTASSIUM CURRENT; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; XENOPUS LAEVIS;

ANIMALS; CHROMANS; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOPUS LAEVIS;

EID: 0035829454     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0109255     Document Type: Article

References (55)

1. Antiarrhythmic drugs
2. Classifying antiarrhythmic actions: By fact or speculation
3. Pharmacology of amiodarone, an antianginal drug with a new biological profile
4. Amiodarone
5. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
6. Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The cardiac arrhythmia supression trial
7. CAST: Implications for drug development
8. The cardiac arrhythmia suppression trial: Background, interim results and implications
9. The coming of age of the class III antiarrhythmic principle: Retrospective and future trends
10. Ventricular arrhythmias: Mechanisms and actions of antiarrhythmic drugs
11. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
12. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
13. Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence
14. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management
15. Torsade de pointes
16. Rate dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of a rapidly activating delayed rectifier K+ current by dofetilide
17. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes
18. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B
19. Two components of cardiac delayed rectifier K+ current
20. Rapid and slow components of delayed rectifier current in human atrial myocytes
21. Ks play a role in the reverse rate dependence of class III agents?
22. Two components of the delayed rectifier potassium current, IK, in rabbit sino-atrial node cells
23. Beta blockade during and after myocardial infarction: An overview of the randomized trials
24. Facilitation of ventricular tachyarrhythmia induction by isoproterenol
25. Use of isoproterenol as an aid to electric induction of chronic recurrent ventricular tachycardia
26. Isoproterenol reversal of antiarrhythmic effects in patients with inducible sustained ventricular tachyarrhythmias
27. Sympathetic activation, ventricular repolarization and Ikr blockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents
28. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans
29. sK channels by the chromanol 293B
30. sK channels in epithelia
31. KVLQT channels are inhibited by the K+ channel blocker 293B
32. + conductance
33. + current, on repolarization in human and guinea pig ventricular myocytes
34. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome
35. Ks -blocker chromanol 293b in intact dog myocardium
36. ks - Blocking agent chromanol 293B on individual muscle layers of the intact canine heart
37. Ks blocking agent chromanol 293b in normal and infarcted canine hearts?
38. Ks by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl1- (2,2,2-trifluoroethyl)-2,3-dihydro-III-benzo[e] [1,4]diazepin-3-yllacetamide
39. Design and synthesis of potent, selective, and orally bioavailable potassium (IKs) blockers
40. Ks -channel blockers: From K(ATP)-channel opener to IKs-channel blocker
41. Airways pharmacology of the potassium channel opener, HOE 234, in guinea pigs: In vitro and in vivo studies
42. Ks cardiac potassium current
43. ks potassium channel
44. (-)-N-[(3r,4s)-6-cyano-3-hydroxy-2,2-dimethyl-chroman-4-yl] -N-methylethansulfonamide semihydrate
45. The effect of catalyst loading and donor ligands in the mn(III)salen catalysed chiral epoxidation of chromenes: Synthesis of BRL 55834
46. Ks Channels by HMR1556
47. Ks-channel blocker HMR 1556 on cardiomyocytes of guinea pig and Xenopus oocytes
48. Ks - Blockade am isolierten Kaninchenherz
49. Ks - Kanalblockers HMR1556 auf die refraktärzeit des vorhofs und ventrikels am Schwein
50. Enantioselective epoxidation of unfunctionalized olefins by (salen)manganese complexes
51. Patch clamp measurements on Xenopus laevis oocytes: Currents through endogenous channels and implanted acetylcholine receptor
52. Maintenance of Xenopus laevis and oocyte injection